Jupiter Neurosciences and Aquanova to develop supplements that target aging as part of new strategic agreement
As part of the new strategic agreement, the jointly-developed products will focus on the “beauty from within” concept. The first three products are expected to launch in Q3 of 2025 through a direct-to-consumer model.
Photo © iStockphoto.com/Jacob Wackerhausen
Jupiter Neurosciences Inc. (Jupiter, FL) and Aquanova AG have entered into a strategic agreement to jointly develop a series of consumer-facing nutritional products that target longevity, aging, and healthspan. Jupiter Neurosciences is a clinical-stage pharmaceutical company while Aquanova AG is a phyto-technology manufacturer that uses its NovaSol technology to deliver micellized ingredients. The two companies have collaborated for eight years, leading to the development of Jotrol, a proprietary resveratrol-based formulation that is advancing to a Phase IIa trial in Parkinson’s Disease.
“As we explore new ways to translate our scientific discoveries into tangible health solutions, we see an immense opportunity in the longevity and healthspan market,” said Christer Rosén, Chairman & CEO of Jupiter Neurosciences. “Aquanova has been an exceptional technology partner, and their expertise in formulation and execution will be instrumental in this venture. We believe that our pharmaceutical-driven approach and the strong clinical foundation behind Jotrol provide a unique advantage in delivering high quality, effective products to consumers.”
According to the press release, as part of the new strategic agreement, the jointly-developed products will focus on the “beauty from within” concept. The first three products are expected to launch in Q3 of 2025 through a direct-to-consumer model.
"We are incredibly proud of our partnership with Jupiter and look forward to the work they are doing to bring life-changing solutions for rare and difficult-to-treat diseases to market in the medicinal sphere and for superior supplement products targeting longevity and healthspan," said Frank Behnam, CEO of Aquanova. "Resveratrol is a powerful ingredient but it suffers from bioavailability and absorption challenges. Our NovaSol technology ensures that resveratrol safely reaches effective levels in the body, without GI-side effects, creating reliable health solutions in many indications."
The products will be launched under a new wholly owned subsidiary, which is expected to generate revenue that will support Jupiter’s ongoing pharmaceutical trials.
Prinova acquires Aplinova to further increase its footprint in Latin America
April 7th 2025Prinova has recently announced the acquisition of Brazilian ingredients distributor Aplinova, which is a provider of specialty ingredients for a range of market segments that include food, beverage, supplements, and personal care.
